This is a summary. To read the whole story subscribe to BostonGlobe.com
BG Medicine Inc., a Waltham life-sciences company, said its quarterly revenue rose 7 percent to $1.15 million, compared with the year-earlier period. The net loss for the quarter came in at 6 cents per share, below the loss of 14 cents a year before. Revenue for the full year 2013 was $4.1 million, a 45 percent increase. Net loss for 2013 was $15.8 million, a 33 percent improvement.The company also said it has been issued a US patent on methods of predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.